ALUMIS INC. (ALMS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0223071020
ALUMIS INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 24.05 m USD |
| Operating income | -453.80 m USD |
| EBIT | -251.89 m USD |
| Net income | -243.33 m USD |
| Diluted EPS – continuing operations | -2.86 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ALUMIS INC.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
More stocks
- Qingdao Kutesmart Co Ltd (300840.SZ)
- CHOICEONE FINANCIAL SERVICES INC (COFS)
- Jiu Han System Technology Co. Ltd. (6903.TWO)
- MHA PLC (MHA.L)
- Restore PLC (RST.L)
- Beijing ConST Instruments Technology Inc (300445.SZ)
- Ability Opto-Electronics Technology Co Ltd (3362.TWO)
- Hainan Haiqi Transportation Group Co Ltd (603069.SS)
- Ovid Therapeutics Inc. (OVID)
- MHP SE (MHPC.L)
- Visco Vision Inc. (6782.TW)
- Yupi Indo Jelly Gum PT Tbk (YUPI.JK)
Not investment advice. All data without warranty, price as of 09.11.2026. Details in the risk notice.